Yahoo! FinanceHome - Yahoo! - Help

Market Guide

[ Stock Screener | Company & Fund Index | Financial Glossary ]

Profile - Celera Genomics (NYSE:CRA)
As of 31-Aug-2001
Enter symbol:
symbol lookup

 
More Info: Quote | Chart | News | Profile | Research | SEC | Msgs | Insider | Options | Financials | Reports
Location
761 Main Avenue
Norwalk, CT 06859
Phone: (203) 762-1000
Fax: (203) 762-6000
Email: webmaster@celera.com
Employees (last reported count): 832
Financial Links
 ·Top Institutional Holders
 ·Top Mutual Fund Holders
 ·Analyst Upgrade/Downgrade History
 ·Historical Quote Data
 ·Free Annual Report
 ·Raw SEC Filings at sec.gov
Competitors:
 ·Sector: Healthcare
 ·Industry: Biotechnology & Drugs
Company Websites
 ·Home Page
 ·Employment
 ·Yahoo! Category

 ·Search Yahoo! for related links...

Ownership
·Insider and 5%+ Owners: 27%
·Over the last 6 months:
 · 4 insider sells; 108.0K shares
  (0.6% of insider shares)
·Institutional: 52% (71% of float)
(361 institutions)
·Net Inst. Buying: 504.0K shares (+1.55%)
(prior quarter to latest quarter)
More From Market Guide
 ·Highlights
 ·Performance
 ·Ratio Comparisons
Business Summary
Celera Genomics Group, a business of Applera Corporation, is engaged principally in the generation, sale and support of genomic information and enabling data management and analysis software. The Celera Genomics Group's customers use this information for commercial applications in the pharmaceutical and life sciences industries in the specific areas of target identification, drug discovery and drug development. The Celera Genomics Group also provides gene discovery, genotyping and related genomics services. The Celera Genomics Group has recently expanded its business into the emerging fields of functional genomics, particularly proteomics and personalized health/medicine.
More from Market Guide: Expanded Business Description

Financial Summary
CRA, a business of Applera Corp., engages in the generation, sale and support of genomic information and related software; discovery, licensing and validation of proprietary gene products; genetic markers, genetic variablity, and related consulting and R&D services. For the nine months ended 3/31/01, sales totaled $61.9 million, up from $27.7 million. Net loss rose 25% to $84.5 million. Results reflect higher subscription agreements, offset by amortization of goodwill.

Recent Earnings Announcement
For the 3 months ended 06/30/2001, revenues were 27,400; after tax earnings were -101,700. (Preliminary; reported in thousands of dollars.)

More from Market Guide: Significant Developments

Officers[Insider Trade Data]
FY1999 Pay

J. Venter, 52
Pres of Clera Genomics and Sr. VP of PE Corp.
$2.1M
Jason Molle
Sr. VP of Sales and Marketing
--  
Peter Barrett, 46
VP
--  
Samuel Broder, 54
VP
--  
James Peck, 36
VP, Product Devel.
--  
Dollar amounts are as of 30-June-1999 and compensation values are for the fiscal year ending on that date; "Pay" is salary, bonuses, etc..
More from Market Guide on Officers & Directors:
Expanded List, Bios, Compensation, Options
Statistics at a Glance -- NYSE:CRAAs of 31-Aug-2001
Price and Volume
52-Week Low
on 22-Mar-2001
$24.00 
Recent Price$26.55 
52-Week High
on 5-Sep-2000
$115.00 
Beta1.70 
Daily Volume (3-month avg)679.6K
Daily Volume (10-day avg)565.0K
Stock Performance
[one-year price graph]
big chart [1d | 5d | 3m | 6m | 1y | 2y | 5y]
52-Week Change-76.4%
52-Week Change
relative to S&P500
-68.3%
Share-Related Items
Market Capitalization$1.63B
Shares Outstanding61.4M
Float44.9M
Dividends & Splits
Annual Dividendnone 
Last Split: 2 for 1 on 22-Feb-2000
Per-Share Data
Book Value (mrq*)$19.77 
Earnings (ttm)-$3.06 
Earnings (mrq)-$1.66 
Sales (ttm)$1.47 
Cash (mrq*)$16.85 
Valuation Ratios
Price/Book (mrq*)1.34 
Price/EarningsN/A 
Price/Sales (ttm)18.03 
Income Statements
Sales (ttm)$89.3M
EBITDA (ttm*)-$185.9M
Income available to common (ttm)-$186.2M
Profitability
Profit MarginN/A 
Operating MarginN/A 
Fiscal Year
Fiscal Year EndsJune 30
Most recent quarter
(fully updated)
31-Mar-2001
Most recent quarter
(flash earnings)
30-June-2001
Management Effectiveness
Return on Assets (ttm)-13.68%
Return on Equity (ttm)-14.81%
Financial Strength
Current Ratio (mrq*)12.85 
Debt/Equity (mrq*)0 
Total Cash (mrq)$0 
Short Interest
As of 8-Aug-2001
Shares Short2.62M
Percent of Float5.8%
Shares Short
(Prior Month)
2.38M
Short Ratio4.19 
Daily Volume626.0K
See Profile Help for a description of each item above;   K = thousands;   M = millions;   B = billions;   mrq = most-recent quarter;   ttm = trailing twelve months;   (as of 30-June-2001, except mrq*/ttm* items as of 31-Mar-2001)

Market Guide offers more in-depth Company Research, Stock Screening, and Hottest Stocks and Industries on over 10,000 U.S. Equities.


Copyright © 2001 Yahoo! Inc. All Rights Reserved. Privacy Policy - Terms of Service
Company information Copyright Market Guide. Historical chart data and daily updates provided by Commodity Systems, Inc. (CSI). Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Yahoo nor any of its data or content providers (such as Market Guide, CSI, etc.) shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon.